ADAPT-IT Raises Question About 4-Dose Schedule of Nivo/Ipi in Patients With Metastatic Melanoma

Source: Targeted Oncology, April 2022

Efficacy and toxicity of standard four dose nivolumab and ipilimumab induction therapy in melanoma to be likely driven by the first 2 doses as demonstrated in the Adaptively Dosed ImmunoTherapy Trial.

Findings from the Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT; NCT03122522) reveal the efficacy and toxicity of standard four dose nivolumab (Opdivo) and ipilimumab (Yervoy) induction therapy in melanoma to be likely driven by the first 2 doses.

While the combination of nivolumab and ipilimumab demonstrates high efficacy, it also has can lead to significant toxicity. The standard treatment for advanced melanoma is 4 doses of the combination followed by nivolumab alone. However, whether or not 4 doses of nivolumab and ipilimumab are needed is unclear.

READ THE ORIGINAL FULL ARTICLE